All current approved antibody treatments for cancer are of the IgG class, but despite their efficacy, there are limitations to their clinical activity, particularly in targeting solid tumours. Epsilogen (formerly known as IGEM Therapeutics) is an innovative immuno-oncology company targeting cancer with the IgE class of antibodies, which have evolved to kill tissue-dwelling multicellular parasites and exhibit several key features that make it ideal for treating solid tumours. The company was spun-out from King's College London and is based on the pioneering work of Dr Sophia Karagiannis and her collaborators at UCL. Epsilogen's lead programme is the world’s first IgE therapeutic to enter the clinic and is currently in a Phase 1/2a trial for ovarian cancer. Alongside Epidarex Capital and Alsa Holdings, UCLTF invested in a £5m Series A round to help Epsilogen develop its pipeline of IgE antibody candidates against a variety of cancers.